Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314906 | 0.81 | HDAC1 (0.40) | NPC1RAB9AKMT2ASMN1; SMN2MAPK14 | |
| SCHEMBL241982 | 0.74 | HDAC1 (0.68) | MAPK14MAPK11 | |
| SCHEMBL3317398 | 0.74 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2AMAPK14 | |
| SCHEMBL124395 | 0.72 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2230140 | 0.72 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31367847 | 0.71 | MAPK14 (0.74) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10282601 | 0.71 | GLA (0.64) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23573216 | 0.71 | NPC1 (0.71) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3086445 | 0.71 | MAPK14 (0.73) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| Bicarbonate SCHEMBL11025569 | 0.71 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004298-A1 | P-38 INHIBITORS | MAPK8, MAPK1, MAP3K8 | NPC1 975/4885RAB9A 1215/4885MEN1 4323/4885 |
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | NPC1 1059/4885RAB9A 1402/4885MEN1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.